AnalysisAstraZeneca's AI-to-Lab Loop Meets a Crowded Oncology Calendar, and the Evidence for It Is Still ThinVia News Editorial Team•Oct 15, 2026
AnalysisAstraZeneca Says Its Data Will Train Better Cancer Drugs. Its Pitch Rests on a Source That Failed Our Check.Via News Editorial Team•Oct 13, 2026
AnalysisAI-Designed Biologics and Personalized mRNA Vaccines: What the Oncology Evidence Supports, and What It Doesn'tVia News Editorial Team•Oct 3, 2026